Background
Methods
Chemicals and antibodies
Datasets and preprocessing
Functional enrichment analysis
Clinical specimens
Immunohistochemistry
Standard for evaluation
Statistical analysis
Results
Expression levels of SOX7 in ovarian cancer and normal tissues
Correlation of reduced SOX7 expression with tumor progression
SOX7 as a negative regulator in Wnt/β-catenin pathway in ovarian cancer
Accession | Term | P-Values | FDR |
---|---|---|---|
GO:0006414 | translational elongation | 4.692062542984977E-29 | 9.047961108371685E-26 |
GO:0006412 | translation | 2.04912911734554E-22 | 3.951447873919316E-19 |
GO:0006396 | RNA processing | 2.7244884076177707E-10 | 5.253780188674284E-7 |
GO:0022613 | ribonucleoprotein complex biogenesis | 1.3552603187281535E-9 | 2.6134227004703803E-6 |
GO:0016071 | mRNA metabolic process | 3.895055800131527E-8 | 7.51104669238778E-5 |
GO:0006397 | mRNA processing | 5.7556740309817435E-8 | 1.1098975527534805E-4 |
GO:0000375 | RNA splicing, via transesterification reactions | 3.5239047199996375E-7 | 6.795316527141715E-4 |
GO:0000377 | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 3.5239047199996375E-7 | 6.795316527141715E-4 |
GO:0000398 | nuclear mRNA splicing, via spliceosome | 3.5239047199996375E-7 | 6.795316527141715E-4 |
GO:0042254 | ribosome biogenesis | 5.134416394199803E-7 | 9.900929787476365E-4 |
GO:0008380 | RNA splicing | 1.103477760861063E-6 | 0.0021278751 |
Gene name | r |
p
|
---|---|---|
CCN-D1
| –0.2753514639 | 0.0555052128 |
CCND2
| –0.2083737906 | 0.1507783665 |
CCND3*
| –0.3789749206 | 0.0072460704 |
CTNNB1 | –0.2298744109 | 0.1120735508 |
JUN*
| –0.328410818 | 0.0212317742 |
MMP7
| –0.1436013727 | 0.3249317121 |
MYC*
| –0.3794897149 | 0.0071609446 |
PPARD(NR1C2)
| 0.0113166546 | 0.9384851238 |
TCF7* | –0.4721329855 | 0.0006148219 |
TCF7L2* | –0.5079689459 | 0.00019461 |
FOSL1
| 0.1976706188 | 0.1733712192 |
LEF1* | –0.4230961749 | 0.0024547299 |
TCF7L1 | 0.014360968 | 0.9219826098 |
Expression of SOX7, cyclin-D1 and COX2 proteins in normal ovarian tissues, borderline ovarian tumors and ovarian cancer
Relations between SOX7 and clinical or pathological characteristics in patients with epithelial ovarian carcinoma
Characteristic | Total | SOX7 expression |
P
| |
---|---|---|---|---|
Over-expression | Low-expression | |||
All cases
| 31 | |||
Pathology type
| NS | |||
Serous
| 26 | 7 | 19 | |
Mucinous
| 2 | 0 | 2 | |
Endometrioid
| 3 | 1 | 2 | |
FIGO stage
| 0.037 | |||
Early (I-II)
| 16 | 7 | 9 | |
Advance (III-IV)
| 15 | 1 | 14 | |
Pathology grade
| NS | |||
Low (1)
| 4 | 1 | 3 | |
High (2 + 3)
| 27 | 7 | 20 | |
Age (years)
| NS | |||
<40
| 0 | 0 | 0 | |
40-60
| 21 | 5 | 16 | |
> 60
| 10 | 3 | 7 | |
Cyclin D1
| rs = –0.583, p < 0.001 | |||
Over-expression
| 26 | 8 | 18 | |
Low-expression
| 5 | 0 | 5 | |
COX2
| rs = –0.618, p < 0.001 | |||
Over-expression
| 27 | 5 | 22 | |
Low-expression
| 4 | 3 | 1 |